Pfizer (PFE) said Monday its phase 3 study of Braftovi combination regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients with a type of metastatic colorectal cancer.
The company said Braftovi, in combination with cetuximab and mFOLFOX6, also showed a significant improvement in overall survival compared to patients receiving standard chemotherapy, with or without bevacizumab, a key secondary endpoint in the trial.
The drugmaker said it plans to share the results with the US Food and Drug Administration to potentially support full approval of the Braftovi combination regimen in patients.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。